Transfusion associated graft-versus-host disease, cytomegalovirus infection and HLA alloimmunization in neonatal and pediatric patients

Transfusion Science

Volumn 21, Issue 1, 1999, Pages 73-95

  Hume, Heather A ^a,b   Preiksaitis, Jutta B ^c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOIMMUNIZATION; BLOOD BANK; BLOOD COMPONENT; BLOOD DONOR; BLOOD TRANSFUSION; CHILD; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; EXCHANGE BLOOD TRANSFUSION; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; IMMUNOCOMPETENCE; NEWBORN; PREMATURITY; REVIEW; SEROCONVERSION;

EID: 0347662180     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(99)00067-3     Document Type: Article

References (137)

1. Von Fliedner V, Higby DJ, Kim U. Graft-versus-host reaction following blood product transfusion. Amer J Med 1982;72:951-61.
2. Ohto H, Anderson KC. Survey of transfusion associated graft-versus-host disease in immunocompetent recipients. Transf Med Rev 1996;10:31-43.
3. Ohto H, Anderson KC. Posttransfusion graft-versus-host disease in Japanese newborns. Transf 1996;36:117-23.
4. Nishimura M, Uchida S, Mitsunaga S, et al. Establishment of a T-cell line from lymphocytes presumably implicated in postransfusion graft-versus-host disease. Vox Sang 1995;68:164-168.
5. Wang L, Tadokoro K, Tokunaga K, Uchida S, Moriyama S, Bannai M, Mitsunaga S, Takai K, Juji T. Restricted use of T-cell receptor Vβ genes in posttransfusion graft-versus-host disease. Transf 1997;37:1184-91.
6. Williamson LM. Transfusion-associated graft-versus-host disease: new insights and a route towards therapy?. Transf Med 1998;8:169-72.
7. Adams PT, Davenport RD, Reardon DA, Roth MS. Detection of circulating donor white blood cells in patients receiving multiple transfusions. Blood 1992;80:551-5.
8. Lee TH, Donegan E, Slichter S, Busch MP. Transient increase in circulating donor leukocytes after allogeneic transfusions in immuno-competent recipients compatible with donor cell proliferation. Blood 1995;85:1207-14.
9. Lee TH, Paglieroni T, Ohto H, Holland PV, Busch MP. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: Frequent long-term microchimerism in severe trauma patients. Blood 1999;93:3127-39.
10. Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, Demaria MA. Male fetal progenitor cells persist in maternal blood for as long as 27 yr postpartum. Proceedings of National Academy of Science USA 1996;93:705-708.
11. Ohto H, Anderson KG. Survey of transfusion-associated graft-versus-host disease in immuno-competent recipients. Transf Med Rev 1996;10:31-43.
12. Hisatomi K, Isomura T, Hirano A, et al. Postoperative erythroderma after cardiac operations. J Thorac Cardiovasc Surg 1992;104:648-653.
13. Hayashi H, Nischiuchi T, Tamura E, et al. Transfusion-associated graft-versus-host disease caused by leukocyte-filtered stored blood. Anesthesiology 1993;79:1419-1421.
14. Hathaway WE, Githens JH, Blackburn WR, Fulginiti V, Kempe CA. Aplastic anemia, histiocytosis and erythrodermia in immunologically deficient children. N Engl J Med 1965;273:953-8.
15. Hathaway WE, Brangle RW, Nelson TI, Rocket IE. Aplastic anemia and alymphocytosis in an infant with hypogrammaglobulinemia: Graft-versus-host reaction. J Pediatr 1966;68:713-22.
16. Brubaker DB. Human Posttransfusion graft-versus-host disease. Vox Sang 1983;45:401-20.
17. Leitman SF, Holland PV. Irradiation of blood products: indications and guidelines. Transf 1985;25:293-303.
18. Holland PV. Prevention of transfusion-associated graft-vs-host disease. Arch Pathol Lab Med 1989;113:285-91.
19. Anderson KC, Weinstein HJ. Transfusion-associated graft-versus-host disease. N Engl J Med 1990;323:315-21.
20. Greenbaum BH. Transfusion-associated graft-versus-host disease: Historical perspectives, incidence, and current use of irradiated blood products. J Clin Oncol 1991;9:1889-902.
21. Linden JV, Pisciotto PT. Transfusion-associated graft-versus-host disease and blood irradiation. Transf Med Rev 1992;11:116-23.
22. Drobyskiy W, Ghibodeau RL, Truitt LA, et al. Third-party - mediated graft-versus-host disease after T-cell - depleted bone marrow transplantation, as demonstrated by hypervariable DNA probers and HLA-DR polymorphism. Blood 1989;74:2285-2294.
23. Sproul AM, Chalmers EA, Mills KI, Burnett AK, Simpson E. Third party mediated graft rejection despite irradiation of blood products. Brit J Haematol 1992;80:251-62.
24. Anderson KC, Goodnough LT, Sayers M, et al. Variation in blood component irradiation practice: Implications for prevention of transfusion-associated graft-versus-host disease. Blood 1991;77:2096-2102.
25. Przepiorka D, Leparc GF, Stovall MA, Werch J, Lichtiger B. Use of irradiated blood components. Practice parameter. Amer J Clin Pathol 1996;106:6-11.
26. Voak D, et al. Prepared by the BCSH (Blood Transfusion Task Force). Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. Transf Med 1996;6:261-271.
27. Grishaber JE, Birney SM, Strauss RG. Potential for transfusion-associated graft-versus-host disease due to apheresis platelets matched for HLA class I antigens. Transf 1993;33:910-4.
28. Shivdasani RA, Haluska FG, Dock NL, et al. Brief report: graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med 1993;328:766-770.
29. Benson K, Marks AR, Marshall MJ, Goldstein JD. Fatal graft-versus-host disease associated with transfusions of HLA-matched, HLA-homozygous platelets from unrelated donors. Transf 1994;34:432-7.
30. Ohto H, Yasuda H, Noguehi M, Abe R. Risk of transfusion-associated graft-versus-host disease as a result of directed donations from relatives. Transf 1992;32:691-6933.
31. Wagner FF, Flegel WA. Transfusion associated graft-versus-host disease: risk due to homozygous HLA haplotypes. Transf 1995;35:284-91.
32. Sanders MR, Graeber JE. Post-transfusion-graft-versus-host disease in infancy. J Pediatr 1990;117:159-63.
33. Ohto H, Anderson KG. Post-transfusion graft-versus-host disease in Japanese newborns. Transf 1996;36: 117-23.
34. Lista GL, Porcelli F, Mercuriali F, Fare M, Taccone F. HLA typing in a neonate with posttransfusional graft vs host disease. Pediatria Medica e Chirurgica 1994;16:285-7.
35. Walker MW, Lovell MA, Kelly TE, Golden W, Saulsbury FT. Multiple areas of intestinal atresia associated with immunodeficiency and posttransfusion graft-versus-host disease. J Pediatr 1993;123:93-5.
36. Funkhouser AW, Vogelsang G, Zehnbauer B, et al. Graft versus host disease after blood transfusions in a premature infant. Pediatrics 1991;87:247-250.
37. Flidel O, Barak Y, Lifschitz-Mercer B, Frumkin A, Mogilner BM. Graft versus host disease in extremely low birth weight neonate. Pediatr 1992;89:689-90.
38. Hatley RM, Reynolds M, Paller AS, Chou P. Graft-versus-host disease following ECMO. J Pediatr Surg 1991;26:317-9.
39. Strauss RG, Levy GJ, Sotelo-Avila C, et al. National survey of neonatal transfusion practices: II. Blood component therapy. Pediatr 1993;91:530-536.
40. Hume H, Blanchette V, Strauss RG, Levy GJ. A survey of Canadian neonatal blood transfusion practices. Transfus Sci 1997;18:71-80.
41. Luban NLC, DePalma L. Transfusion-associated graft-versus-host disease in the neonate-expanding the spectrum of disease. Transf 1996;36:101-3.
42. Ohto H, Anderson KC. Are guidelines for use of gamma irradiation for the prevention of transfusion-associated graft-versus-host disease adequate for newborns?. Transf Med 1997;7:171-3.
43. Williamson LM, Warwick RM. Untitled response to the letter cited in Ref. [42]. Transf Med 1997;7:173.
44. Towbin JA, Greenberg F. Genetic syndromes and clinical molecular genetics. In: Garson A, Bricker JT, Fisher DJ, Neish SR, editors. The Science and Practice of Pediatric Cardiology, 2nd ed. Williams & Wilkins 1997, vol. II, 2627-2699.
45. Roxby D, Simmer K, Seshadri R. Transfusion associated graft-versus-host disease in an infant following cardiac surgery. Transf 1997;37:42S.
46. Klein C, Fraitag S, Foulon E, Raffoux C, Bodemer C, Blanche S. Moderate and transient transfusion-associated cutaneous graft-versus-host disease in a child infected by human immunodeficiency virus. Amer J Med 1996;101:445-6.
47. Ammann AJ. Absence of graft-versus-host disease in AIDS is a consequence of HIV-1 infection of CD4+ T cells. J AIDS 1993;6:1224-7.
48. Popovsky MA, Benson K, Glassman AB, Hume HA, Oberman PT, Anderson KC. Transfusion practices in human immunodeficiency virus-infected patients. Transf 1998;35:612-6.
49. Moroff G, Leitman SF, Luban NLC. Principles of blood irradiation, dose validation, and quality control. Transf 1997;37:1084-92.
50. Center for Biologics Evaluation and Research. License amendments and procedures for gamma irradiation of blood products. Bethesda, MD: food and Drug Administration, July 22, 1993.
51. Davey RJ. The effect of irradiation on blood components. In: Baldwin ML, Jeffries I, editors. Irradiation of blood components, Bethesda, MD: American Association of Blood Banks, 1992: 41-62.
52. Button LN, DeWolf WC, Neuberger PE, Jacobson MS, Kevin SV. The effects of irradiation on blood components. Transf 1981;21:419-26.
53. Davey RJ, McCoy NC, Yu M, Sullivan JA, Spiegel DM, Leitman SF. The effect of prestorage irradiation on posttransfusion red cell survival. Transf 1992;32: 525-8.
54. Moroff G, Holme S, Aubuchon J, et al. Storage of red cells and platelets following gamma irradiation. Vox Sang 1994 (Abstr. Suppl 2); 67:42.
55. Strauss RG. Routinely washing irradiated red cells before transfusion seems unwarranted. Transf 1990;30:675-7.
56. Moroff G, Luban NLC. The irradiation of blood and blood components to prevent graft-versus-host disease: Technical issues and guidelines. Transf Med Rev 1997;11:15-26.
57. Love EM, Williamson LM, Lowe S, Cohen H. Serious hazards of transfusion (SHOT) scheme: The first annual report 1996-97. Transf Med 1998;8(S1):6.
58. van Prooijen HC, Aarts-Riemens MI, Grijzenhout MA, van Weelden H. Ultraviolet irradiation modulates MHC-alloreactive cytotoxic T-cell precursors involved in the onset of graft-versus-host disease. Brit J Haematol 1992;81:73-6.
59. Yasukawa M, Shinozaki F, Hato T, et al. Successful treatment of transfusion-associated graft-versus-host disease. Brit J Haematol 1994;86:831-836.
60. Yasukawa M, Hatoh T. A transfusion-associated GVHD case rescued with cyclosporin A and OKT3 (Japanese). Nihon Yuketsu Gakkai Zasshi (Japan J Transfus Med.), 1994;40:149-152.
61. Nishimura M, Akaza T, Tadokoro K, Juji T. Potential usefulness of protease inhibitor and chloroquine in the treatment of transfusion-associated graft-versus-host disease. Transf 1997;37:768-70.
62. Nishimura M, Akaza T, Tadokoro K, Juji T. Potential usefulness of photochemotherapy using 8-methoxypsoralen in the treatment of posttransfusion graft-versus-host disease. Vox Sang 1998;75:306-7.
63. Nishimura M, Hidaka N, Akaza T, Tadokoro K, Juji T. Immunosupressive effects of chloroquine: potentiel effectiveness for treatment of post-transfusion graft-versus-host disease. Transf Med 1998;8:209-14.
64. Tegtmeir GE. Cytomegalovirus and blood transfusion. In: Dodd RY, Barker LF, editors. Infection, Immunity and Blood Transfusion. New York, NY:Liss, 1985, 175-199.
65. Tolpin MD, Stewart JA, Warren D, et al. Transfusion transmission of Cytomegalovirus confirmed by restriction endonuclease analysis. J Pediatr 1985;107:953-956.
66. Meyers JD, Flournoy N, Thomas ED. Risk factors for Cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;3:478-88.
67. Bowden R, Sayers M. The risk of transmitting cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression. J Infect Dis 1988;157:523-9.
68. Jackson JB, Erice A, Englund JA, Edson JR, Balfour Jr HH. Prevalence of cytomegalovirus antibody in hemophiliacs and homosexuals infected with human immunodeficiency virus type. Transf 1988;28:187-9.
69. Revello MG, Zavattoni M, Sarasini A, et al. Human cytomegalovirus in blood of immunocompetent persons during primary infection: Prognostic implications for pregnancy. J Infect Dis 1998;177:1170-1175.
70. Taylor-Wiedeman J, Sissons JGP, Borysiewicz LK, et al: Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 1991;72:2059-2064.
71. Diosi P, Moldovan E, Tomescu N. Latent cytomegalovirus infection in blood donors. Br Med J 1969;4:660-2.
72. Soderberg-Naucler C, Fish KN. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997;91:119-26.
73. Hahn G, Jores R. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci 1998;95:3937-42.
74. Beneke JS, Tegtmeier GE, Alter HJ, et al. Relation of titers of antibodies to CMV in blood donors to the transmission of cytomegalovirus infection. J Infect Dis 1984;150:883-888.
75. Lamberson HV, McMillan JA, Weiner LB, et al. Prevention of transfusion-associated cytomegalovirus (CMV) infection in neonates by screening blood donors for IgM to CMV. J Infect Dis 1988;157:820-823.
76. Jackson JB, Orr HT, McCullough JJ, et al. Failure to detect human cytomegalovirus DNA in IgM-seropositive blood donors by spot hybridization. J Infect Dis 1987;156:1013-1016.
77. Preiksaitis JK, Desai S, Vaudry W, et al. Transfusions-and community-acquired cytomegalovirus infection in children with malignant disease: a prospective study. Transf 1997;37:941-946.
78. Bevan IS, Daw RA, Day PJR, et al. Polymerase chain reaction for detection of human cytomegalovirus infection in a blood donor population. Brit J Haematol 1991;78:94-99.
79. Larsson S, Soderberg-Naucler C, Wang FZ, et al. Cytomegalovirus DNA can be detected in peripheral blood mononuclear cells from all seropositive and most seronegative healthy blood donors over time. Transf 1998;38:271-278.
80. Stanier P, Taylor DL, Kitchen AD, et al. Persistence of cytomegalovirus in mononuclear cells in peripheral blood from blood donors. Br Med J 1989;299:897-898.
81. James DJ, Sikotra S, Sivakumaran M, et al. The presence of free infectious cytomegalovirus (CMV) in the plasma of donated CMV-seropositive blood and platelets. Transf Med 1997;7:123-126.
82. Kumar A, Nankervis GA, Cooper AR, et al. Acquisition of cytomegalovirus infection in infants following exchange transfusion: A prospective study. Transf 1980;20:327-331.
83. Benson JWT, Bodden SJ, Tobin JO. Cytomegalovirus and blood transfusion in neonates. Arch Dis Child 1979;54:538-41.
84. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986;314:1006-1010.
85. Miller WJ, McCullough J, Balfour HH, et al. Prevention of cytomegalovirus infection following bone marrow transplantation: A randomized trial of blood product screening. Bone Marrow Transplant 1991;7:227-34.
86. Preiksaitis JK, Indications JK. Indications for the use of cytomegalovirus-seronegative blood products. Transf Med Rev 1991;5:1-17.
87. Lang DJ, Ebert PA. Reduction of postperfusion cytomegalovirus-infections following the use of leukocyte depleted blood. Transf 1997;17:391-5.
88. Demmler GJ, Brady MT, Bijou H, et al. Posttransfusion cytomegalovirus infections in neonates: Role of saline-washed red cells. J Pediatr 1986;108:762-765.
89. Luban NLC, Williams AE, McDonald M, et al. Low incidence of cytomegalovirus infection in neonates transfused with washed red blood cells. Amer J Dis Child 1987;141:416-419.
90. Brady MT, Milam JT, Anderson DC, et al. Use of deglycerolized red cells to prevent posttransfusion infection with cytomegalovirus in neonates. J Infect Dis 1984;150:334-339.
91. Taylor BJ, Jacobs RF, Baker RL, et al. Frozen deglycerolized blood prevents transfusion-acquired cytomegalovirus infections in neonates. Pediatr Infect Dis 1986;5:188-191.
92. Simon TL, Johnson JD, Koffler H, et al. Impact of previously frozen deglycerolized red blood cells on cytomegalovirus transmission to newborn infants. Plasma Ther Transfus Technol 1987;8:51-56.
93. Verdonck LF, deGraan-Hentzen YCE. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transpl 1987;2:72-8.
94. Murphy MF. Use of leucocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukaemia. Brit J Haematol 1998;70:253-5.
95. De Graan-Hentzen YCE, Gratama JW, Mudde GC, et al. Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood products. Transfusion 1989;29:757-760.
96. DeWitte T, Schattenberg A. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus unscreened blood-bank donors. Transpl 1990;50:964-8.
97. Bowden RA, Slichter SH. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention or primary cytomegalovirus infection after marrow transplant. Blood 1991;78:246-50.
98. Van HC, Prooijen JJ. Prevention of primary transfusion-associated cytomegalovirus infection in bone marrow transplant recipients by the removal of white cells from blood components with high-affinity filters. Brit J Haematol 1994;87:144-7.
99. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;86:3598-3603.
100. AABB 1997. Leukocyte reduction for the prevention of transfusion-transmitted cytomegalovirus. American Association of Blood Banks, Association Bulletin 97-2.
101. Napier A, et al. British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines on the clinical use of leucocyte-depleted blood. Transf Med 1998;8:59-71.
102. Ledent E, Berlin G. Factors influencing white cell removal from red cell concentrates by filtration. Transf 1996;36:714-8.
103. Sirchia G, Rebulla P, Sabbioneda L, et al. Optimal conditions for white cell reduction in red cells by filtration at the patient's bedside. Transf 1996;36:322-327.
104. Wilhelm JA, Matter L, Schopfer K. The risk of transmitting cytomegalovirus to patients receiving blood transfusion. J Infect Dis 1986;154:169-71.
105. Preiksaitis JK, Brown L, McKenzie M. The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression. J Infect Dis 1988;157:523-9.
106. Baumgartner JD, Glauser MP, Burgo-Black AL, et al. Severe cytomegalovirus infection in multiply transfused, splenectomized, trauma patients. Lancet 1982;2:63-66.
107. Drew WL, Miner RC. Transfusion-related cytomegalovirus infection following non-cardiac surgery. JAMA 1982;247:2389-91.
108. Chou S. Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med 1986;314:1418-23.
109. Chou S. Cytomegalovirus infection and reinfection transmitted by heart transplantation. J Infect Dis 1987;155:1054-5.
110. Grundy JE, Super M, Sweny P, et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: Reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988;2:132-135.
111. Chandler SH, Handsfield HH, McDougall JK. Isolation of multiple strains of cytomegalovirus from women attending a clinic for sexually transmitted diseases. J Infect Dis 1987;155:655-60.
112. Spector SA, Hirata KK, Newman TR. Identification of multiple cytomegalovirus strains in homosexual men with acquired immunodeficiency syndrome. J Infect Dis 1984;150:953-6.
113. Snydman DR, Werner BG, Meissner HC, et al. Use of cytomegalovirus immunoglobulin in multiple transfused premature neonates. Pediatr Infect Dis J 1995;14:34-40.
114. Yeager AS, Palumbo PE Malachowski N, et al. Sequelae of maternally derived cytomegalovirus infections in premature infants. J Pediatr 1983;102:918-922.
115. Ballow M, Cates KL, Rowe JC, et al. Development of the immune system in very low birth weight (less than 1500 g) premature infants: Concentrations of plasma immunoglobulins and patterns of infections. Pediatr Res 1986;20:899-904.
116. Adler SP, McVoy MM. Cytomegalovirus infections in seropositive patients after transfusion: the effect of red cell storage and volume. Transf 1989;29:667-71.
117. Tierney AJ, Higa TE. Disseminated cytomegalovirus infection after extracorporeal membrane oxygenation. Pediatr Infect Dis J 1992;11:241-2.
118. Manno CS, Luban NLC, et al. Blood Component therapy in neonates: Results of 1994 survey. Transf 1996;36:17S.
119. Alford CA, Stagno S, Pass RF, et al. Congenital and perinatal cytomegalovirus infections. Rev Infect Dis 1990;12:S745-753.
120. Drew WL. Cytomegalovirus infection in patients with AIDS. J Infect Dis 1988;158:449-56.
121. Skolnik PR, Kosloff BR, Hirsch MS. Bidirectional interactions between human immunodeficiency virus type aaa and cytomegalovirus. J Infect Dis 1988;157:508-14.
122. de Montalembert M, Girot R, Mattlinger B, Lefrere JJ. Transfusion-dependent thalassemia: viral complications (epidemiology and follow-up). Seminars in Hematology 1995;32:280-7.
123. Schiffer CA, Dutcher JP, Aisner J, et al. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983;62:815-820.
124. Sniecinski I, O'Donnel MR, Nowicki B. Prevention of refractoriness and HLA-alloimmunization using filered blood products. Blood 1988;71:1402-7.
125. Andreu G. Dewailly J, Leberre C, et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988;72:964-969.
126. Van Marwijk Kooy M, Van Prooijen HC, Moes M, et al. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization. A prospective, randomized trial. Blood 1991;77:201-205.
127. Oksanen K, Kekomaki R, Runtu T, et al. Prevention of alloimmunization in patients with acute leukemia by the use of white cell-reduced blood components. A randomized trial. Transf 1991;31:588-594.
128. Williamson LM, Wimperis JZ, Williamson P, et al. Bedside filtration of blood products in the prevention of HLA alloimmunization. A prospective randomized study. Blood 1994;83:3028-3035.
129. Sinthnicolaas K, Van Marwijk Kooij M, Van prooijen HC, et al. Leukocyte depletion of random single-donor platelet transfusions does not prevent secondary human leukocyte antigen-alloimmunization and refractoriness. A randomized prospective study. Blood 1995;85:824-828.
130. The Trial to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;337:1861-1869.
131. Vamvakas EC. Meta-analysis of randomized controlled trials of the efficacy of white cell reduction in preventing HLA-alloimmunization and refractoriness to random-donor platelet transfusions. Transf Med Rev 1998;12:258-70.
132. Saarinen UM, Kekomäki R, Siimes MA, Myllylä G. Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components. Blood 1990;75:512-7.
133. Saarinen UM, Koskimies S, Myllylä G. Systematic use of leukocyte-free blood components to prevent alloimmunization and platelet refractoriness in multitransfused children with cancer. Vox Sang 1993;65:286-92.
134. Hogge DE, McConnell M, Jacobson C, Sutherland HJ, Benny WB, Massing BG. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients. Transf 1995;35:645-52.
135. Heddle NM, Blajchman MA. The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions. Blood 1995;85:603-6.
136. Sirchia G, Rebulla P. Evidence-based medicine. The case for white cell reduction. Transf 1997;37:543-9.
137. Friedman DF, Lukas MB, Jawad A, et al. Alloimmunization to platelets in heavily transfused patients with sickle cell disease. Blood 1996;88:3216-3222.